• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

评估前列腺影像报告和数据系统第 2.1 版的 4 类和 5 类假阳性病变与临床显著前列腺癌的相关性。

Assessment of prostate imaging reporting and data system version 2.1 false-positive category 4 and 5 lesions in clinically significant prostate cancer.

机构信息

Department of Radiology, The First Affiliated Hospital of Shenzhen University, Health Science Center, Shenzhen Second People's Hospital, 3002 SunGangXi Road, Shenzhen, 518035, China.

Department of Ultrasonography, The First Affiliated Hospital of Shenzhen University, Health Science Center, Shenzhen Second People's Hospital, 3002 SunGangXi Road, Shenzhen, 518035, China.

出版信息

Abdom Radiol (NY). 2021 Jul;46(7):3410-3417. doi: 10.1007/s00261-021-03023-w. Epub 2021 Mar 12.

DOI:10.1007/s00261-021-03023-w
PMID:33710384
Abstract

PURPOSE

To determine the incidence and false-positive rates of clinically significant prostate cancer (CSPC) in prostate imaging reporting and data system (PI-RADS) category 4 and 5 lesions using PI-RADS v2.1.

METHODS

One hundred and eighty-two lesions in 169 subjects with a PI-RADS score of 4 or 5 were included in our study. Lesions with clinically insignificant prostate cancer (CIPC) or benign pathologic findings were reviewed and categorized by a radiologist. The initial comparison of demographic and clinical data was performed by t-test and χ test, and then the logistic regression model was used to determine factors associated with CIPC or benign pathological findings.

RESULTS

Of the 182 PI-RADS category 4 and 5 lesions, 84.6% (154/182) were prostate cancer (PCa), 73.1% (133/182) were CSPC, and 26.9% (49/182) were CIPC or benign pathologic findings. The false-positive cases included 44.9% (22/49) with inflammation, 42.9% (21/49) with CIPC, 8.2% (4/49) with BPH nodules and 4.1% (2/49) with normal anatomy cases. In multivariate analysis, factors associated with CIPC or benign features included those in both the peripheral zone (PZ) and central gland (CG) (odds ratio [OR] 0.062; p = 0.003) and a low prostate-specific antigen density (PSAD) (OR 0.34; p = 0.012).

CONCLUSION

The integration of clinical information (PSAD and lesion location) into mpMRI to identify lesions helps with obtaining a clinically significant diagnosis and decision-making.

摘要

目的

使用 PI-RADS v2.1 确定 PI-RADS 类别 4 和 5 病变中临床显著前列腺癌(CSPC)的发生率和假阳性率。

方法

我们的研究纳入了 169 名患者的 182 个 PI-RADS 评分 4 或 5 的病变。由放射科医生对具有临床意义不显著前列腺癌(CIPC)或良性病理发现的病变进行回顾和分类。通过 t 检验和 χ 检验进行初始的人口统计学和临床数据比较,然后使用逻辑回归模型确定与 CIPC 或良性病理发现相关的因素。

结果

在 182 个 PI-RADS 类别 4 和 5 病变中,84.6%(154/182)为前列腺癌(PCa),73.1%(133/182)为 CSPC,26.9%(49/182)为 CIPC 或良性病理发现。假阳性病例包括 44.9%(22/49)炎症,42.9%(21/49)CIPC,8.2%(4/49)BPH 结节和 4.1%(2/49)正常解剖病例。多变量分析表明,与 CIPC 或良性特征相关的因素包括外周带(PZ)和中央腺体(CG)(比值比 [OR] 0.062;p=0.003)和低前列腺特异性抗原密度(PSAD)(OR 0.34;p=0.012)。

结论

将临床信息(PSAD 和病变位置)整合到 mpMRI 中有助于识别病变,从而获得有临床意义的诊断和决策。

相似文献

1
Assessment of prostate imaging reporting and data system version 2.1 false-positive category 4 and 5 lesions in clinically significant prostate cancer.评估前列腺影像报告和数据系统第 2.1 版的 4 类和 5 类假阳性病变与临床显著前列腺癌的相关性。
Abdom Radiol (NY). 2021 Jul;46(7):3410-3417. doi: 10.1007/s00261-021-03023-w. Epub 2021 Mar 12.
2
MRI-Ultrasound Fusion Targeted Biopsy of Prostate Imaging Reporting and Data System Version 2 Category 5 Lesions Found False-Positive at Multiparametric Prostate MRI.多参数前列腺 MRI 发现前列腺影像报告和数据系统版本 2 类别 5 病变的 MRI-超声融合靶向活检为假阳性。
AJR Am J Roentgenol. 2018 May;210(5):W218-W225. doi: 10.2214/AJR.17.18680. Epub 2018 Feb 28.
3
Risk of Clinically Significant Prostate Cancer Associated With Prostate Imaging Reporting and Data System Category 3 (Equivocal) Lesions Identified on Multiparametric Prostate MRI.多参数前列腺 MRI 检出前列腺影像报告和数据系统(PI-RADS)类别 3(可疑)病变与临床显著前列腺癌风险的相关性。
AJR Am J Roentgenol. 2018 Feb;210(2):347-357. doi: 10.2214/AJR.17.18516. Epub 2017 Nov 7.
4
[Preliminary applicability evaluation of Prostate Imaging Reporting and Data System version 2 diagnostic score in 3.0T multi-parameters magnetic resonance imaging combined with prostate specific antigen density for prostate cancer].[前列腺影像报告和数据系统第2版诊断评分在3.0T多参数磁共振成像联合前列腺特异性抗原密度用于前列腺癌的初步适用性评估]
Zhonghua Yi Xue Za Zhi. 2017 Dec 19;97(47):3693-3698. doi: 10.3760/cma.j.issn.0376-2491.2017.47.003.
5
Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer.前列腺影像报告和数据系统(PI-RADS)评分与指数病变和多灶性、临床显著前列腺癌的相关性。
Eur Urol Oncol. 2018 May;1(1):29-36. doi: 10.1016/j.euo.2018.01.002. Epub 2018 May 15.
6
Comparison of Biparametric and Multiparametric MRI for Clinically Significant Prostate Cancer Detection With PI-RADS Version 2.1.基于PI-RADS v2.1的双参数和多参数MRI在检测临床显著性前列腺癌中的比较
J Magn Reson Imaging. 2021 Jan;53(1):283-291. doi: 10.1002/jmri.27283. Epub 2020 Jul 2.
7
Predictive clinical features for negative histopathology of MRI/Ultrasound-fusion-guided prostate biopsy in patients with high likelihood of cancer at prostate MRI: Analysis from a urologic outpatient clinic1.基于泌尿科门诊患者的研究:磁共振成像/超声融合引导前列腺活检阴性组织学预测的临床特征在前列腺磁共振成像高度怀疑癌症患者中的分析 1.
Clin Hemorheol Microcirc. 2020;76(4):503-511. doi: 10.3233/CH-209225.
8
Usefulness of LacdiNAc-glycosylated Prostate-specific Antigen Density for Predicting Pathological Findings of Magnetic Resonance Imaging-transrectal Ultrasound Fusion Image-guided Prostate Biopsy for the Patients With Highest Prostate Imaging Reporting and Data System Category ≥3.乳糖胺糖基化前列腺特异性抗原密度对预测前列腺影像报告和数据系统类别≥3的患者磁共振成像-经直肠超声融合图像引导下前列腺穿刺活检病理结果的效用。
J Urol. 2023 Jan;209(1):187-197. doi: 10.1097/JU.0000000000002958. Epub 2022 Sep 6.
9
Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients.前列腺影像报告和数据系统(PI-RADS)评分与前列腺特异性抗原(PSA)密度相结合可预测初次接受前列腺穿刺活检患者的活检结果。
BJU Int. 2017 Feb;119(2):225-233. doi: 10.1111/bju.13465. Epub 2016 Apr 1.
10
Can Prostate Imaging Reporting and Data System Version 2 reduce unnecessary prostate biopsies in men with PSA levels of 4-10 ng/ml?前列腺影像报告和数据系统第 2 版能否减少 PSA 水平在 4-10ng/ml 的男性进行不必要的前列腺活检?
J Cancer Res Clin Oncol. 2018 May;144(5):987-995. doi: 10.1007/s00432-018-2616-6. Epub 2018 Mar 5.

引用本文的文献

1
Clinical and Imaging Predictors of False-Positive and False-Negative Results in Prostate Multiparametric MRI Using PI-RADS Version 2.使用PI-RADS第2版的前列腺多参数MRI中假阳性和假阴性结果的临床及影像预测因素
Radiol Imaging Cancer. 2025 Mar;7(2):e240019. doi: 10.1148/rycan.240019.
2
Interpretable machine learning model for predicting clinically significant prostate cancer: integrating intratumoral and peritumoral radiomics with clinical and metabolic features.用于预测临床显著前列腺癌的可解释机器学习模型:整合瘤内和瘤周放射组学与临床及代谢特征
BMC Med Imaging. 2024 Dec 30;24(1):353. doi: 10.1186/s12880-024-01548-2.
3

本文引用的文献

1
MRI-Ultrasound Fusion Targeted Biopsy of Prostate Imaging Reporting and Data System Version 2 Category 5 Lesions Found False-Positive at Multiparametric Prostate MRI.多参数前列腺 MRI 发现前列腺影像报告和数据系统版本 2 类别 5 病变的 MRI-超声融合靶向活检为假阳性。
AJR Am J Roentgenol. 2018 May;210(5):W218-W225. doi: 10.2214/AJR.17.18680. Epub 2018 Feb 28.
2
Multi-institutional nomogram predicting benign prostate pathology on magnetic resonance/ultrasound fusion biopsy in men with a prior negative 12-core systematic biopsy.多机构列线图预测既往 12 针系统穿刺阴性的男性患者磁共振/超声融合活检的前列腺良性病理。
Cancer. 2018 Jan 15;124(2):278-285. doi: 10.1002/cncr.31051. Epub 2017 Oct 4.
3
Development and validation of a novel nomogram to avoid unnecessary biopsy in patients with PI-RADS category ≥ 4 lesions and PSA ≤ 20 ng/ml.
开发和验证一种新的列线图,以避免在 PI-RADS 类别≥4 病变且 PSA≤20ng/ml 的患者中进行不必要的活检。
World J Urol. 2024 Aug 23;42(1):495. doi: 10.1007/s00345-024-05202-y.
4
Diagnostic value of combining PI-RADS v2.1 with PSAD in clinically significant prostate cancer.PI-RADS v2.1 联合 PSAD 对临床显著前列腺癌的诊断价值。
Abdom Radiol (NY). 2022 Oct;47(10):3574-3582. doi: 10.1007/s00261-022-03592-4. Epub 2022 Jul 5.
Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.
联合临床参数和多参数磁共振成像进行前列腺癌高危风险建模-个体化风险分层可减少不必要的活检。
Eur Urol. 2017 Dec;72(6):888-896. doi: 10.1016/j.eururo.2017.03.039. Epub 2017 Apr 8.
4
The Value of PSA Density in Combination with PI-RADS™ for the Accuracy of Prostate Cancer Prediction.PSAD 值联合 PI-RADS™ 对前列腺癌预测准确性的价值。
J Urol. 2017 Sep;198(3):575-582. doi: 10.1016/j.juro.2017.03.130. Epub 2017 Mar 31.
5
Prospective Evaluation of PI-RADS™ Version 2 Using the International Society of Urological Pathology Prostate Cancer Grade Group System.PI-RADS™ 版本 2 的前瞻性评估:采用国际泌尿病理学会前列腺癌分级分组系统。
J Urol. 2017 Sep;198(3):583-590. doi: 10.1016/j.juro.2017.03.131. Epub 2017 Mar 31.
6
In-Bore 3-T MR-guided Transrectal Targeted Prostate Biopsy: Prostate Imaging Reporting and Data System Version 2-based Diagnostic Performance for Detection of Prostate Cancer.3T磁共振引导下经直肠前列腺靶向活检:基于前列腺影像报告和数据系统第2版检测前列腺癌的诊断性能
Radiology. 2017 Apr;283(1):130-139. doi: 10.1148/radiol.2016152827. Epub 2016 Nov 18.
7
Accuracy and agreement of PIRADSv2 for prostate cancer mpMRI: A multireader study.前列腺癌磁共振成像(mpMRI)中PIRADSv2的准确性和一致性:一项多阅片者研究
J Magn Reson Imaging. 2017 Feb;45(2):579-585. doi: 10.1002/jmri.25372. Epub 2016 Jul 8.
8
Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients.前列腺影像报告和数据系统(PI-RADS)评分与前列腺特异性抗原(PSA)密度相结合可预测初次接受前列腺穿刺活检患者的活检结果。
BJU Int. 2017 Feb;119(2):225-233. doi: 10.1111/bju.13465. Epub 2016 Apr 1.
9
Current role of multiparametric magnetic resonance imaging for prostate cancer.多参数磁共振成像在前列腺癌中的当前作用
Quant Imaging Med Surg. 2015 Oct;5(5):754-64. doi: 10.3978/j.issn.2223-4292.2015.10.08.
10
PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2.PI-RADS前列腺影像报告和数据系统:2015版,第2版
Eur Urol. 2016 Jan;69(1):16-40. doi: 10.1016/j.eururo.2015.08.052. Epub 2015 Oct 1.